These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 11156079)

  • 1. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
    Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
    Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
    Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
    Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy.
    Lee H; Ahn YC; Pyo H; Kim B; Oh D; Nam H; Lee E; Sun JM; Ahn JS; Ahn MJ; Park K; Choi YS; Kim J; Zo JI; Shim YM
    Ann Surg Oncol; 2014 Jun; 21(6):2083-90. PubMed ID: 24522994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.
    Veeramachaneni NK; Feins RH; Stephenson BJ; Edwards LJ; Fernandez FG
    Ann Thorac Surg; 2012 Sep; 94(3):922-6; discussion 926-8. PubMed ID: 22742842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.
    Takeda S; Maeda H; Okada T; Yamaguchi T; Nakagawa M; Yokota S; Sawabata N; Ohta M
    Eur J Cardiothorac Surg; 2006 Jul; 30(1):184-9. PubMed ID: 16730452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of multi-level N2-positive non-small cell lung cancer according to lymph node staging using endobronchial ultrasound-transbronchial biopsy.
    Yoon HY; Lee JC; Kim SW; Kim HR; Kim YH; Choi SH; Kim SS; Song SY; Choi EK; Jang SJ; Choi CM
    Thorac Cancer; 2018 Jun; 9(6):684-692. PubMed ID: 29607613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy.
    Voltolini L; Luzzi L; Ghiribelli C; Paladini P; Di Bisceglie M; Gotti G
    Eur J Cardiothorac Surg; 2001 Dec; 20(6):1106-12. PubMed ID: 11717012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.
    Cho JH; Kim J; Kim K; Shim YM; Kim HK; Choi YS
    World J Surg; 2012 May; 36(5):1199-1205. PubMed ID: 22374538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.
    Mamon HJ; Yeap BY; Jänne PA; Reblando J; Shrager S; Jaklitsch MT; Mentzer S; Lukanich JM; Sugarbaker DJ; Baldini EH; Berman S; Skarin A; Bueno R
    J Clin Oncol; 2005 Mar; 23(7):1530-7. PubMed ID: 15735128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
    Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.
    Suntharalingam M; Paulus R; Edelman MJ; Krasna M; Burrows W; Gore E; Wilson LD; Choy H
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):456-63. PubMed ID: 22543206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.